ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic ...

Orthokeratology lenses have a microbial keratitis incidence rate similar to daily wear contact lenses, based on a large ...

Differentiating hereditary from nonhereditary retinoblastoma is now possible overnight, improving early intervention ...

A study by a team of Chinese researchers highlights the potential of optical coherence tomography angiography (OCTA) in ...

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.